Pembrolizumab 25 MG/1 ML Intravenous Solution
Phase 2Active 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Uveal Melanoma
Conditions
Metastatic Uveal Melanoma
Trial Timeline
Jul 7, 2022 → Nov 15, 2026
NCT ID
NCT05282901About Pembrolizumab 25 MG/1 ML Intravenous Solution
Pembrolizumab 25 MG/1 ML Intravenous Solution is a phase 2 stage product being developed by Merck for Metastatic Uveal Melanoma. The current trial status is active. This product is registered under clinical trial identifier NCT05282901. Target conditions include Metastatic Uveal Melanoma.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Uveal Melanoma were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
12
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05282901 | Phase 2 | Active |
Competing Products
20 competing products in Metastatic Uveal Melanoma